Albert David Limited has informed the Exchange about change in Management
ALBERTDAVD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Albert David Limited's Board met on August 2, 2025 and approved the unaudited financial results for Q1 FY26 (quarter ended June 30, 2025). Revenue from operations fell to ₹7,056.64 lakhs from ₹8,935.64 lakhs in the same quarter last year, a decline of about 21%. Net profit dropped sharply to ₹793.76 lakhs from ₹1,884.44 lakhs, a fall of nearly 58%, with EPS at ₹13.91 versus ₹33.02 previously. The Board also appointed Dr. Rajiv Anant Desai (age 63) as an Additional Non-Executive Independent Director for a five-year term, subject to shareholder approval via postal ballot. Dr. Desai brings over 38 years of pharmaceutical experience, including a prior role as EVP Global Corporate Quality at Lupin Limited, and is not related to any existing directors or promoters. The statutory auditor issued an unmodified limited review report on the results.
The significant year-on-year decline in both revenue and profit for Q1 FY26 is a negative signal for near-term earnings momentum, though the addition of a senior pharma industry expert to the Board may support long-term governance and strategic direction. Shareholders should watch for the postal ballot outcome and any management commentary on the Q1 slowdown.